Off-Label Pacira Warning Letter Dropped From FDA's Website
This article was originally published in The Gray Sheet
FDA has apparently taken down a warning letter from its website describing off-label marketing violations by Pacira Pharmaceuticals, a drug company that is suing the agency over First Amendment free speech rights. The agency’s response in the lawsuit is due this month.
You may also be interested in...
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.